This HTRF kit detects changes of cAMP accumulation in response to Gi coupled GPCR activation or inhibition
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).
Feature | Specification |
---|---|
Application | Second Messenger Detection |
Sample Volume | 9 µL |
This HTRF kit detects changes of cAMP accumulation in response to Gi coupled GPCR activation or inhibition
Based on HTRF technology, the kit contains all the reagents needed to quantify cAMP, ensuring that you benefit from a complete tool for your needs.
Revvity's HTRF cAMP kits are best suited for measuring cAMP modulations in response to Gi-activation, leveraging an optimized combination of robustness and sensitivity.
Application |
Second Messenger Detection
|
---|---|
Brand |
HTRF
|
Detection Modality |
HTRF
|
Product Group |
Kit
|
Sample Volume |
9 µL
|
Shipping Conditions |
Shipped Ambient
|
Target Class |
GPCR
|
Technology |
TR-FRET
|
Therapeutic Area |
Cardiovascular
Infectious Diseases
Metabolism/Diabetes
NASH/Fibrosis
Neuroscience
Oncology & Inflammation
Rare Diseases
|
Unit Size |
1,000 Assay Points
|
cAMP kits are based on a competitive format involving a specific antibody labeled with d2 (acceptor) and cAMP coupled to cryptate (donor). This enables the direct characterization of all types of compounds acting on Gi-coupled receptors in either adherent or suspension cells. Native cAMP produced by cells competes with cryptate -labeled cAMP for binding to monoclonal anti-cAMP.
The protocol is simple and straightforward, with just two incubation steps: - Cell stimulation by the target compounds - cAMP detection using HTRF reagents
Designed with signal performance in mind, the kit offers a tailored standard curve ideally suited to the study of Gi coupled GPCRs.
S/B | IC10 nM | IC50 nM | IC90 nM | |
---|---|---|---|---|
cAMP - Gi | 31 | 0.8 | 3.0 | 12 |
The cAMP Gi kit allows enhanced performances for Gi coupled receptor assessment.
The data below shows the pharmacological validation of the Gi kit for the stably expressing delta opioid receptor cell line. Agonists and antagonists were well characterized, showing potency in agreement with the literature.
CHO cells stably expressing the delta opioid receptor (DOR) at 6000 cells/well were treated with the SNC-162, a reference agonist, for 45 min.
SNC-162 was well characterized, displaying the right potency in good correlation with the literature.
DOR Agonist SNC-162 | cAMP Gi | cAMP Gs dynamic |
---|---|---|
Optimal Cell density / well | 6000 | 12000 |
S/B | 4.5 | 2.3 |
EC50 (nM) | 1.6 | 1.9 |
CHO cells stably expressing the delta opioid receptor (DOR) at 6000 cells/well were treated with the SNC-162 agonist for 45 min at the EC90 value (10 nM), which is the optimal concentration to use for the antagonist mode experiment.
Fitting the serial dilutions of the Naltrindole and the Naloxone antagonists enabled IC50 calculation of the compounds (potency), which was in perfect correlation with the literature.
cAMP Gi | cAMP Gs dynamic | |||
---|---|---|---|---|
DOR Antagonists | Naltrindole | Naloxone | Naltrindole | Naloxone |
Optimal Cells density / well | 6000 | 6000 | 12000 | 12000 |
S/B | 4 | 4.2 | 2.3 | 2.3 |
IC50 (nM) | 1.4 | 868 | 2.4 | 934 |
Are you looking for resources, click on the resource type to explore further.
Discover the versatility and precision of Homogeneous Time-Resolved Fluorescence (HTRF) technology. Our HTRF portfolio offers a...
This guide provides you an overview of HTRF applications in several therapeutic areas.
Obesity is a complex condition characterized by excessive fat accumulation, posing significant health and socioeconomic challenges...
Are you looking for technical documents related to the product? We have categorized them in dedicated sections below. Explore now.
We are here to answer your questions.